Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 24, 2018

Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies (S20.004)

Qi Zhang, Dustin D. Ruff, Eric M. Pearlman, Sriram Govindan, Sheena K. Aurora
First published April 9, 2018,
Qi Zhang
1Eli Lilly and Company Indianapolis IN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dustin D. Ruff
1Eli Lilly and Company Indianapolis IN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric M. Pearlman
1Eli Lilly and Company Indianapolis IN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sriram Govindan
2Eli Lilly Services India Pvt. Ltd Bengaluru India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheena K. Aurora
1Eli Lilly and Company Indianapolis IN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies (S20.004)
Qi Zhang, Dustin D. Ruff, Eric M. Pearlman, Sriram Govindan, Sheena K. Aurora
Neurology Apr 2018, 90 (15 Supplement) S20.004;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To assess if there were any differential treatment effects in patients who had failed ≥2 previous preventives versus those who had not through a subgroup analysis of three Phase 3 studies of galcanezumab.

Background: Galcanezumab (GMB) is a humanized monoclonal antibody against calcitonin gene-related peptide under development for prevention of migraine.

Design/Methods: EVOLVE-1 (NCT02614183), EVOLVE-2 (NCT02614196) and REGAIN (NCT02614261) were Phase 3, randomized, double-blind, placebo-controlled studies in patients with episodic (EVOLVE-1/2) or chronic (REGAIN) migraine. Patients were randomized 2:1:1 to receive placebo, GMB_120 mg or GMB_240 mg during double-blind treatment period lasting six months (EVOLVE-1/2) or three months (REGAIN). Subgroup analysis was conducted for change from baseline in number of monthly migraine headache days (MHD) and ≥50% response (reduction in number of MHD) for patients who failed ≥2 prior preventive therapies (yes vs no). Subgroup-by-treatment interactions were calculated using linear or generalized linear mixed models.

Results: In the integrated analysis of EVOLVE studies and in the REGAIN study, GMB_120 mg/240 mg statistically significantly improved (p<0.001) overall mean reduction of monthly MHD compared with placebo in both subgroups of patients. For the subgroup who failed prior preventives, reductions were: EVOLVE: placebo: 0.81; GMB_120mg: 3.45; GMB_240mg: 3.85; REGAIN: placebo: 1.44; GMB_120mg: 5.91; GMB_240mg: 3.30. Significant treatment-by-subgroup interactions were seen for GMB_240mg (EVOLVE studies) and for GMB_120mg (REGAIN) suggesting better efficacy compared with placebo for these doses in patients who failed prior preventives. Mean percentage of patients with ≥50% response were significantly higher, compared with placebo, for both subgroups in EVOLVE studies and REGAIN study.

Conclusions: GMB_120mg/240mg is efficacious compared with placebo in reducing monthly MHDs in both patients who failed and did not fail ≥2 prior preventives. Treatment-by-subgroup interactions maybe driven by lower placebo response in patients who failed preventives previously as magnitude of change for GMB-treated patients were similar in both subgroups.

Study Supported by: Eli Lilly and Company

Disclosure: Dr. Zhang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Zhang has received compensation for serving on the Board of Directors of Eli Lilly and Company. Dr. Ruff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Pearlman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Govindan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Aurora has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (4)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise